Partnerships

In August 2010 Bexion Pharmaceuticals was selected by the National Cancer Institute (NCI) for a research collaboration to study Bexion’s first-in-class nanotherapy treatment for solid tumors. The research will be conducted by the NCI’s Nanotechnology Characterization Laboratory (NCL), part of a major program, the Alliance for Nanotechnology in Cancer, to advance the medical applications of nanotechnology. The initial NCL efforts will focus on the characterization of Bexion’s product for its absorption, distribution and toxicity properties in both in vitro and in vivo studies.

The intent of these studies is to produce data for Bexion to support its filings with the U.S. Food and Drug Administration (FDA). The cost of these studies is paid for by the NCL. The agreement is part of the NCI’s Advanced Technology Partnerships Initiative, which seeks to accelerate the delivery of new products to cancer patients.

National Cancer Institute

www.cancer.gov

Nanotechnology Characterization Laboratory

ncl.cancer.gov